<DOC>
	<DOCNO>NCT01633372</DOCNO>
	<brief_summary>This study itacitinib ( INCB039110 ) patient myelofibrosis . This study evaluate safety efficacy parameter itacitinib ( INCB039110 ) .</brief_summary>
	<brief_title>An Open Label Study INCB039110 Administered Orally Patients With Myelofibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<criteria>Must diagnose PMF , PPVMF PETMF confirm bone marrow biopsy . Must score least 1 point Dynamic International Prognostic Scoring System ( DIPSS ) prognostic risk factor peripheral blast count &lt; 10 % Screening Baseline hematology assessment . Subjects must discontinue drug use treat underlie MF disease later Day 14 . Subjects must hemoglobin value &gt; /= 8.0g/dL willing receive blood transfusion , platelet count &gt; /=50x10^9/L absolute neutrophil count ( ANC ) &gt; /= 1x10^9/L . Subjects must palpable spleen history splenectomy Active symptom screen visit Women pregnant breastfeeding , men woman comply requirement avoid father child become pregnant , respectively . Subjects impair liver function , end stage renal disease dialysis clinically significant concurrent infection require therapy . Subjects unstable cardiac function invasive malignancy previous 2 year except treat basal squamous carcinoma skin , completely resect intraepithelial carcinoma cervix completely resect papillary thyroid follicular thyroid cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Primary Myelofibrosis</keyword>
	<keyword>PMF</keyword>
	<keyword>Post Polycythemia Vera Fibrosis</keyword>
	<keyword>PPV-MF</keyword>
	<keyword>Post Essential Thrombocythemia Myelofibrosis</keyword>
	<keyword>PET-MF</keyword>
</DOC>